Sodium Intake Not Linked to Multiple Sclerosis Progression

This article originally appeared here.
Share this content:
Sodium Intake Not Linked to Multiple Sclerosis Progression
Sodium Intake Not Linked to Multiple Sclerosis Progression

TUESDAY, June 13, 2017 (HealthDay News) -- There is no association between average 24-hour urine sodium levels and conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (MS), according to a study published online May 26 in the Annals of Neurology.

Kathryn C. Fitzgerald, Sc.D., from the Johns Hopkins School of Medicine in Baltimore, and colleagues examined whether a high-salt diet is associated with faster conversion from CIS to MS. A total of 465 patients with CIS provided a median of 14 spot urine samples during five-year follow-up of the BENEFIT trial.

The researchers observed no correlation between average 24-hour urine sodium levels and conversion to clinically definite MS over the five-year follow-up (hazard ratio, 0.91 95 percent confidence interval, 0.67 to 1.24 per 1 g increase in estimated daily sodium intake). There were also no associations with clinical or magnetic resonance imaging (MRI) outcomes (new active lesions after six months: hazard ratio, 1.05 [95 percent confidence interval, 0.97 to 1.13]; relative change in T2 lesion volume: −0.11 [95 percent confidence interval, −0.25 to 0.04]; change in Expanded Disability Status Scale: −0.01 [95 percent confidence interval: −0.09 to 0.08]; relapse rate: hazard ratio, 0.78 [95 percent confidence interval, 0.56-1.07]). In categorical analyses using quintiles, the results were similar.

"Our results, based on multiple assessments of urine sodium excretion over five years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity," the authors write.

One author is an employee of Bayer AG.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths